Home › Research › Costs and economics
Adjusted-Dose Warfarin versus Aspirin for Preventing Stroke in Patients with Atrial Fibrillation
Robert G. Hart, Lesly A. Pearce, Maria I. Aguilar. Annals of Internal Medicine, 2007-10-16
Topic: Drug trials: efficacy and safety
Letters16 October 2007Adjusted-Dose Warfarin versus Aspirin for Preventing Stroke in Patients with Atrial FibrillationRobert G. The study's important results indicate that the relative efficacy and safety of warfarin for stroke prevention can be extended to very elderly patients who are managed by nonspecialists. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Antithrombotic Therapy in Atrial Fibrillation Study Group. [The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin]. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Aguilar Metrics Cited ByVorhofflimmernHemorrhagic transformation and stroke recurrence in children with cardiac disease receiving antithrombotic therapy for secondary stroke preventionControversies: Stroke Prevention in Chronic Kidney Disease2021 Korean Heart Rhythm Society Guidelines: Management of Atrial Fibrillation in Specific Clinical SettingsGuía ESC 2020 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración de la European Association of Cardio-Thoracic Surgery (EACTS)Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)Mechanical valve replacement without anticoagulation: a case reportEffects of rivaroxaban on activated clotting time in catheter ablation for atrial fibrillation in Chinese patientsDifferences in anticoagulation strategy and outcome in atrial fibrillation patients with chronic kidney disease: a CODE-AF registry studyDoes the presence of diabetes mellitus confer an increased risk of stroke in patients with atrial fib
Key findings
- Letters16 October 2007Adjusted-Dose Warfarin versus Aspirin for Preventing Stroke in Patients with Atrial FibrillationRobert G.
- The study's important results indicate that the relative efficacy and safety of warfarin for stroke prevention can be extended to very elderly patients who are managed by nonspecialists.
- Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.
- Antithrombotic Therapy in Atrial Fibrillation Study Group. [The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin].
- Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study.
New to this subject? Start with our plain-English guide: Costs & economics →
Study details
- Study designrandomized controlled trial
- Participants973
- Evidence strengthHigh
How this study scored 76/100
Published in a leading specialty journal, and it is a randomised controlled trial. Scored zero for effect reported because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 44 of the 58 points we could judge it on, which is 76 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Annals of Internal Medicine) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A randomised controlled trial |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2007 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 973 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 1 / 2 | Randomised (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 17938402) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 44 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 44 of the 58 points we could judge it on is 76 out of 100. |
| Total | 76 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007). Adjusted-Dose Warfarin versus Aspirin for Preventing Stroke in Patients with Atrial Fibrillation. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-147-8-200710160-00018
Vancouver
Hart RG, Pearce LA, Aguilar MI. Adjusted-Dose Warfarin versus Aspirin for Preventing Stroke in Patients with Atrial Fibrillation. Annals of Internal Medicine. 2007. doi:10.7326/0003-4819-147-8-200710160-00018. PMID: 17938402.
BibTeX
@article{hart2007-17938402,
author = {Hart, Robert G. and Pearce, Lesly A. and Aguilar, Maria I.},
title = {{Adjusted-Dose Warfarin versus Aspirin for Preventing Stroke in Patients with Atrial Fibrillation}},
journal = {Annals of Internal Medicine},
year = {2007},
doi = {10.7326/0003-4819-147-8-200710160-00018},
pmid = {17938402},
url = {https://doi.org/10.7326/0003-4819-147-8-200710160-00018}
}
Related studies in Costs and economics
Also tagged “deaths”
109 studies in the library carry the topic tag “deaths”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 109 tagged studies.